Depressive Disorder News and Research

RSS

Neurocrine Biosciences announces GSK561679 antagonist's efficacy in major depressive disorder

Neurocrine Biosciences, Inc. today announced top-line efficacy and safety results from a Phase II clinical trial utilizing Corticotropin Releasing Factor (CRF1) receptor antagonist GSK561679 in patients currently experiencing a major depressive episode.

15 Sep 2010

NIH awards $6.5M for pharmacogenomics study of key mood-stabilizing drug for bipolar disorder

An international team, led by University of California, San Diego School of Medicine researchers, has been awarded a $6.5 million grant from the National Institutes of Health (NIH) to study the pharmacogenomics of a key mood-stabilizing drug used to treat bipolar disorder.

9 Sep 2010

UC San Diego researchers receive grant to study pharmacogenomics for bipolar disorder

8 Sep 2010

Research reveals need for initiatives to prevent, treat substance abuse when fighting violent crime

A new study from Sweden's Karolinska Institutet suggests that bipolar disorder or manic-depressive disorder does not increase the risk of committing violent crime. Instead, the over-representation of individuals with bipolar disorder in violent crime statistics is almost entirely attributable to concurrent substance abuse.

8 Sep 2010

Rexahn submits Phase IIb protocol to FDA for study of Serdaxin for major depressive disorder

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it has submitted a Phase IIb protocol to the U.S. Food and Drug Administration (FDA) for the clinical study of Serdaxin for the treatment of major depressive disorder (MDD).

7 Sep 2010

SAMe dietary supplement effective for major depressive disorders: Study

A new study conducted by investigators at Harvard Medical School and Massachusetts General Hospital (MGH) suggests that S-Adenosyl Methionine (SAMe), an over-the-counter dietary supplement, can be an effective, relatively well-tolerated, adjunctive treatment for adults with major depressive disorders who do not respond to their treatment with antidepressant medication.

2 Sep 2010

23rd ECNP Press conference on impact of circadian rhythms on human brain

All humans are synchronised to the rhythmic light-dark changes that occur on a daily basis. Rhythms in physiological and biochemical processes and behavioural patterns persist in the absence of all external 24-hour signals from the physical environment, with a period that is close to 24 hours

30 Aug 2010

USFDA approves Sun Pharma's generic Venlafaxine Hydrochloride Extended Release tablets ANDA

Sun Pharma announced that USFDA has granted an approval for an Abbreviated New Drug Application (ANDA) to market a generic version of Venlafaxine Hydrochloride Extended Release tablets.

19 Aug 2010

Labopharm second-quarter total revenue increases to $6.8 million

Labopharm Inc. today reported its financial results for the second quarter and first six months ended June 30, 2010. All figures are in Canadian dollars unless otherwise stated.

12 Aug 2010

Labopharm launches antidepressant OLEPTRO for major depressive disorder in U.S.

Labopharm Inc. today announced that OLEPTRO(TM) (trazodone hydrochloride extended-release tablets), a novel once-daily formulation of the antidepressant trazodone, has been launched in the United States by its joint venture with Gruppo Angelini, Angelini Labopharm. OLEPTRO(TM) is indicated for the treatment of major depressive disorder (MDD) in adults. The efficacy of OLEPTRO(TM) has been established in a trial of outpatients with MDD as well as in trials with the immediate release formulation of trazodone.

11 Aug 2010

Older Americans suffer from full-blown depression: Report

Maureen Duffy's memories of her grandmother are cloudy. Not because of time, but by a condition that cast a shadow over the woman Duffy had visited as a child.

10 Aug 2010

Clinical Data first-quarter gross revenue increases 52% to $6.2 million

Clinical Data, Inc. today announced operational and financial results for the first quarter ended June 30, 2010, noting key accomplishments including the acceptance of the Company's new drug application (NDA) for vilazodone by the U.S. Food and Drug Administration (FDA) and the successful completion of a public offering .

9 Aug 2010

Widespread sexual violence, human rights abuses in DRC linked with physical, mental health outcomes

A recent survey of men and women in specific territories of Eastern Democratic Republic of the Congo found sexual violence and human rights violations were prevalent and were associated with physical and mental health outcomes, according to an article in the August 4 issue of JAMA, a theme issue on violence and human rights.

5 Aug 2010

Pfizer announces unrestricted access to patient assessment aids for mental disorders

As part of its commitment to improving the quality of patient care, Pfizer today announced that it will make available assessment scales used by physicians and others in the healthcare community to support the evaluation and diagnosis of patients suffering from certain mental disorders.

23 Jul 2010

Gene expression profiling may provide molecular diagnostic tool to diagnose depression

Blood tests have been extremely important tools aiding doctors in making medical diagnoses and in guiding the treatment of many diseases. However, psychiatry is one area of medicine where there are few diagnostic blood tests.New scientific fields may someday generate blood tests that can be used for these purposes. Some of the areas under increasingly intensive study are genetics, the study of variations in the genes that can be extracted from blood cells, and genomics like proteomics, the measurement of the levels of specific proteins in the blood, and gene expression profiling, which measures the levels of RNA produced from DNA as an indication of the level of the "activity" of particular genes.

23 Jul 2010

Caraco Pharmaceutical Laboratories begins marketing bupropion hydrochloride extended release tablets

Caraco Pharmaceutical Laboratories, Ltd. has started shipping bupropion hydrochloride extended release tablets. This product was recently approved by the US Food and Drug Administration (FDA) for Sun Pharma's Abbreviated New Drug Application (ANDA). These bupropion hydrochloride extended release tablets, 100 mg, 150 mg, and 200 mg, are therapeutically equivalent to GlaxoSmithKline's Wellbutrin SR® Extended Release tablets.

22 Jul 2010

Actavis Group receives FDA approval to market Bupropion HCl SR tablets

Actavis Group, the international generic pharmaceuticals company, today announced that it has received approval from the U.S. Food & Drug Administration to market Bupropion HCl Extended-Release tablets 100mg and 200mg. Distribution of the product will commence immediately.

22 Jul 2010

Forest Laboratories reports first-quarter diluted EPS of $0.39

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, announced that diluted earnings per share equaled $0.39 in the first quarter of fiscal 2011. Excluding the charge related to the United States Department of Justice investigations described below, and a charge of $50.0 million, or $0.17 per share net of tax, for a new product licensing fee, non-GAAP earnings per share for the first fiscal quarter were $0.95 per share.

20 Jul 2010

People with alcohol-related problems find comfort in speaking to clergy: Study

Persons with alcohol problems are finding comfort in speaking about their situation to clergy, a new study shows. Among 1,910 people with any alcohol-related problems, 14.7 percent said they used clergy services.The study, from researchers at the University of Michigan Health System and Saint Louis University, also indicates the majority of those who used services from clergy also used professional services at some point; only 0.5 percent used clergy services exclusively for their alcohol use-related problem.

15 Jul 2010

Anxiety disorders associated with higher risk of cardiovascular events, deaths in heart disease patients

Among patients with heart disease, anxiety disorders appear to be associated with a higher risk of stroke, heart attack, heart failure and death, according to a report in the July issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

6 Jul 2010